De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure

Molecular Immunology

Volumn 45, Issue 1, 2008, Pages 106-116

  Wang, Jianing ^a   Feng, Jiannan ^a   Shi, Ming ^a   Qian, Lu ^a   Chen, Liyong ^a   Yu, Ming ^a   Xu, Ruonan ^a   Shen, Beifen ^a   Guo, Ning ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Antagonistic peptide; Coiled coil; Epitope; ErbB2; Molecular modeling

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; HYBRID PROTEIN; TRASTUZUMAB;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; DRUG DESIGN; DRUG INHIBITION; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MODEL; MOUSE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CHO CELLS; COMPUTER-AIDED DESIGN; CRICETINAE; CRICETULUS; DIMERIZATION; EPITOPES; HUMANS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ESCHERICHIA COLI;

EID: 34548272147     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.05.001     Document Type: Article

References (44)

1. Albanell J., Codony J., Rovira A., Mellado B., and Gascon P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv. Exp. Med. Biol. 532 (2003) 253-268
2. Alroy I., and Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410 (1997) 83-86
3. Azios N.G., Romero F.J., Denton M.C., Doherty J.K., and Clinton G.M. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene 20 (2001) 5199-5209
4. Blanchet J.S., Valmori D., Dufau I., Ayyoub M., Nguyen C., Guillaume P., Monsarrat B., Cerottini J.C., Romero P., and Gairin J.E. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. J. Immunol. 167 (2001) 5852-5861
5. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney Jr. D.W., and Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 (2003) 756-760
6. Cohen C., and Parry D.A. Alpha-helical coiled coils and bundles: how to design an alpha-helical protein. Proteins 7 (1990) 1-15
7. Coussens L., Yang-Feng T.L., Liao Y.C., Chen E., Gray A., McGrath J., Seeburg P.H., Libermann T.A., Schlessinger J., and Francke U. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230 (1985) 1132-1139
8. Doherty J.K., Bond C., Jardim A., Adelman J.P., and Clinton G.M. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 10869-10874
9. Efimov V.P., Engel J., and Malashkevich V.N. Crystallization and preliminary crystallographic study of the pentamerizing domain from cartilage oligomeric matrix protein: a five-stranded alpha-helical bundle. Proteins 24 (1996) 259-262
10. Graus-Porta D., Beerli R.R., Daly J.M., and Hynes N.E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16 (1997) 1647-1655
11. Hu P., Feng J., Zhou T., Wang J., Jing B., Yu M., Hu M., Zhang X., Shen B., and Guo N. In vivo identification of the interaction site of ErbB2 extracellular domain with its autoinhibitor. J. Cell Physiol. 205 (2005) 335-343
12. Jhabvala-Romero F., Evans A., Guo S., Denton M., and Clinton G.M. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2. Oncogene 22 (2003) 8178-8186
13. Jiang B., Liu W., Qu H., Meng L., Song S., Ouyang T., and Shou C. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2. J. Biol. Chem. 280 (2005) 4656-4662
14. Justman Q.A., and Clinton G.M. Herstatin, an autoinhibitor of the human epidermal growth factor receptor 2 tyrosine kinase, modulates epidermal growth factor signaling pathways resulting in growth arrest. J. Biol. Chem. 277 (2002) 20618-20624
15. Kammerer R.A. Alpha-helical coiled-coil oligomerization domains in extracellular proteins. Matrix Biol. 15 (1997) 555-565
16. Kohn W.D., Mant C.T., and Hodges R.S. Alpha-helical protein assembly motifs. J. Biol. Chem. 272 (1997) 2583-2586
17. Lupas A. Coiled coils: new structures and new functions. Trends Biochem. Sci. 21 (1996) 375-382
18. Malashkevich V.N., Kammerer R.A., Efimov V.P., Schulthess T., and Engel J. The crystal structure of a five-stranded coiled coil in COMP: a prototype ion channel?. Science 274 (1996) 761-765
19. McLachlan A.D., and Stewart M. Tropomyosin coiled-coil interactions: evidence for an unstaggered structure. J. Mol. Biol. 98 (1975) 293-304
20. Molina M.A., Codony-Servat J., Albanell J., Rojo F., Arribas J., and Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61 (2001) 4744-4749
21. Morgelin M., Heinegard D., Engel J., and Paulsson M. Electron microscopy of native cartilage oligomeric matrix protein purified from the Swarm rat chondrosarcoma reveals a five-armed structure. J. Biol. Chem. 267 (1992) 6137-6141
22. O'Neil K.T., and DeGrado W.F. A thermodynamic scale for the helix-forming tendencies of the commonly occurring amino acids. Science 250 (1990) 646-651
23. O'Shea E.K., Klemm J.D., Kim P.S., and Alber T. X-ray structure of the GCN4 leucine zipper, a two-stranded, parallel coiled coil. Science 254 (1991) 539-544
24. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19 (2000) 3159-3167
25. Park B.W., Zhang H.T., Wu C., Berezov A., Zhang X., Dua R., Wang Q., Kao G., O'Rourke D.M., Greene M.I., and Murali R. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol. 18 (2000) 194-198
26. Penuel E., Akita R.W., and Sliwkowski M.X. Identification of a region within the ErbB2/HER2 intracellular domain that is necessary for ligand-independent association. J. Biol. Chem. 277 (2002) 28468-28473
27. Ranson M., and Sliwkowski M.X. Perspectives on anti-HER monoclonal antibodies. Oncology 63 Suppl. 1 (2002) 17-24
28. Riemer A.B., Kraml G., Scheiner O., Zielinski C.C., and Jensen-Jarolim E. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu-a new method of epitope definition. Mol. Immunol. 42 (2005) 1121-1124
29. Riese D.J., and Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20 (1998) 41-48
30. Roskoski Jr. R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun. 319 (2004) 1-11
31. Schafmeister C.E., LaPorte S.L., Miercke L.J., and Stroud R.M. A designed four helix bundle protein with native-like structure. Nat. Struct. Biol. 4 (1997) 1039-1046
32. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 26 (1999) 71-77
33. Simmerman H.K., Kobayashi Y.M., Autry J.M., and Jones L.R. A leucine zipper stabilizes the pentameric membrane domain of phospholamban and forms a coiled-coil pore structure. J. Biol. Chem. 271 (1996) 5941-5946
34. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (1987) 177-182
35. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., and Ullrich A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
36. Sodek J., Hodges R.S., Smillie L.B., and Jurasek L. Amino-acid sequence of rabbit skeletal tropomyosin and its coiled-coil structure. Proc. Natl. Acad. Sci. U.S.A. 69 (1972) 3800-3804
37. Spek E.J., Bui A.H., Lu M., and Kallenbach N.R. Surface salt bridges stabilize the GCN4 leucine zipper. Protein Sci. 7 (1998) 2431-2437
38. Starovasnik M.A., Braisted A.C., and Wells J.A. Structural mimicry of a native protein by a minimized binding domain. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 10080-10085
39. Staverosky J.A., Muldoon L.L., Guo S., Evans A.J., Neuwelt E.A., and Clinton G.M. Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma. Clin. Cancer Res. 11 (2005) 335-340
40. Stern D.F., Heffernan P.A., and Weinberg R.A. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Mol. Cell Biol. 6 (1986) 1729-1740
41. Stetefeld J., Jenny M., Schulthess T., Landwehr R., Engel J., and Kammerer R.A. Crystal structure of a naturally occurring parallel right-handed coiled coil tetramer. Nat. Struct. Biol. 7 (2000) 772-776
42. Tzahar E., Pinkas-Kramarski R., Moyer J.D., Klapper L.N., Alroy I., Levkowitz G., Shelly M., Henis S., Eisenstein M., Ratzkin B.J., Sela M., Andrews G.C., and Yarden Y. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J. 16 (1997) 4938-4950
43. Wang J.N., Feng J.N., Yu M., Xu M., Shi M., Zhou T., Yu X.D., Shen B.F., and Guo N. Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitory monoclonal antibodies. Mol. Immunol. 40 (2004) 963-969
44. Yip Y.L., and Ward R.L. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol. Immunother. 50 (2002) 569-587